13
June
2019
|
10:47 PM
America/New_York

New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

Bristol-Myers Squibb (BMS) reports prospective analysis data of the Early AMPLE head-to-head trial evaluating the molecular and cellular mechanisms of rheumatoid arthritis treatments and interference with disease progression, will be presented as a late-breaking oral presentation at the Annual European Congress of Rheumatology (EULAR 2019).

BMS quoted Vivian P. Bykerk, BSc, MD, FRCPC, rheumatologist at HSS, regarding the impact of the research, who said, “This research advances our understanding of these mechanisms and the value of the applicability of precision medicine for patients with highly active, progressive rheumatoid arthritis.”

Read the BMS press release at news.bms.com.

Additional coverage: Medicine Matters-Rheumatology, Rheumatology Consultant